In subgroups of patients defined by clinical and tumor characteristics (stage, ER status, HER2 status, breast cancer subtype and oncological treatment), aspirin use after diagnosis was associated with a reduced risk of breast cancer-specific death among women with stage I tumors (HR 0.53, 95% CI 0.29–0.96) (Table 3). Here, ESR1 is linked to breast carcinoma.